Roche Bonds With Monte Rosa To Degrade Molecular Glues
Deal Expands Reach Of Protein Degradation Platform
Deal Snapshot: Monte Rosa Therapeutics received $50m up front and may earn more than $2bn in milestone fees from Roche for molecular glue degraders to treat cancer and neurological diseases.
